1-(3-nitro-phenyl)-ethanone thiosemicarbazone | 132898-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-nitro-phenyl)-ethanone thiosemicarbazone
• 英文别名: 1-(3-Nitro-phenyl)-aethanon-thiosemicarbazon；(2E)-2-[1-(3-nitrophenyl)ethylidene]hydrazinecarbothioamide；[(E)-1-(3-nitrophenyl)ethylideneamino]thiourea
• CAS: 132898-27-2
• 化学式: C₉H₁₀N₄O₂S
• 分子量: 238.27
• InChiKey: NFJPLHYZNDOBTD-IZZDOVSWSA-N

物化性质

• 沸点：
  399.4±44.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-nitro-phenyl)-ethanone thiosemicarbazone 在 potassium bromate 、 mercury(II) diacetate 作用下， 以 高氯酸 、 溶剂黄146 为溶剂， 生成 间硝基苯乙酮
  参考文献：
  名称：

  Mercury(II) acetate-assisted oxidative hydrolysis of thiosemicarbazones of benzaldehyde, acetophenone and benzophenone by potassium bromate

  摘要：

  Thiosemicarbazones of benzaldehydes, acetophenones and benzophenones are oxidatively hydrolysed by potassium bromate, {Br(v)}, in the presence of mercury(II) acetate, as Hg(II) forms a complex with sulphur atoms, increasing the lability of the N-H bond. The rates of these reactions are less susceptible to the electronic influence of the substituents at the phenyl ring compared with other oxidants, showing that N-bromate ester formation is the rate-determining step of this reaction. Such N-bromate ester formation seems to occur more readily with Hg(II)-sulphur complexes.

  DOI：

  10.1039/p29910001523
• 作为产物：
  描述：

  氨基硫脲 、 间硝基苯乙酮 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 1-(3-nitro-phenyl)-ethanone thiosemicarbazone
  参考文献：
  名称：

  4-（3-硝基苯基）噻唑-2-基hydr衍生物作为抗氧化剂和选择性hMAO-B抑制剂：合成，生物活性和计算分析

  摘要：

  抽象的 设计，合成和评估了一系列新的4-（3-硝基苯基）噻唑-2-基hydr衍生物，以评估它们对人单胺氧化酶（hMAO）A和B同工型的抑制作用。为了建立稳固的结构-活性关系，将不同的（未）取代的（杂）芳族取代基与N的N 1连接。生物试验的结果表明，hydrazothiazole核轴承中的C4存在下，在所述官能化的苯基环的元与硝基位置代表着一个重要的药效特征，以获得选择性和可逆的人MAO-B抑制神经变性疾病的治疗。此外，最有效的和选择性的MAO-B抑制剂进行了评价，在硅片作为潜在的胆碱酯酶（AChE / BuChE）抑制剂，并在体外具有抗氧化活性。从分子建模研究中获得的结果为所报道的MAO抑制特性的多重相互作用和结构要求提供了见识。

  DOI：

  10.1080/14756366.2019.1571272

文献信息

• 4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis
  作者：Daniela Secci、Simone Carradori、Anél Petzer、Paolo Guglielmi、Melissa D’Ascenzio、Paola Chimenti、Donatella Bagetta、Stefano Alcaro、Gokhan Zengin、Jacobus P. Petzer、Francesco Ortuso

  DOI：10.1080/14756366.2019.1571272

  日期：2019.1.1

  Abstract A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives were designed, synthesised, and evaluated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms. Different (un)substituted (hetero)aromatic substituents were linked to N1 of the hydrazone in order to establish robust structure–activity relationships. The results of the biological testing demonstrated

  抽象的 设计，合成和评估了一系列新的4-（3-硝基苯基）噻唑-2-基hydr衍生物，以评估它们对人单胺氧化酶（hMAO）A和B同工型的抑制作用。为了建立稳固的结构-活性关系，将不同的（未）取代的（杂）芳族取代基与N的N 1连接。生物试验的结果表明，hydrazothiazole核轴承中的C4存在下，在所述官能化的苯基环的元与硝基位置代表着一个重要的药效特征，以获得选择性和可逆的人MAO-B抑制神经变性疾病的治疗。此外，最有效的和选择性的MAO-B抑制剂进行了评价，在硅片作为潜在的胆碱酯酶（AChE / BuChE）抑制剂，并在体外具有抗氧化活性。从分子建模研究中获得的结果为所报道的MAO抑制特性的多重相互作用和结构要求提供了见识。
• Thiadiazoline derivative
  申请人：Murakata Chikara

  公开号：US20060074113A1

  公开（公告）日：2006-04-06

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级烯基或类似物；R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物；R2代表-C（═W）R6或类似物；R3代表氢原子，-C（═WA）R6A或类似物。该抗肿瘤剂包含由上述通式（I）表示的噻二唑啉衍生物或其药理学上可接受的盐作为活性成分。
• THIADIAZOLINE DERIVATIVE
  申请人：MURAKATA Chikara

  公开号：US20080207706A1

  公开（公告）日：2008-08-28

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其包括由上述一般式（I）表示的噻二唑啉衍生物或其药学上可接受的盐作为活性成分，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低碳基，取代或未取代的低炔基，取代或未取代的低烯基或类似物; R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物; R2代表-C（═W）R6或类似物; R3代表氢原子，-C（═WA）R6A或类似物。
• Mitotic kinesin inhibitor
  申请人：Murakata Chikara

  公开号：US20070155804A1

  公开（公告）日：2007-07-05

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，其包括由通式（I）表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1代表氢原子等，R2代表氢原子，-C（═W）R6（其中W代表氧原子或硫原子，R6代表取代或未取代的低级烷基等）等，R3代表-C（═Z）R19（其中Z代表氧原子或硫原子，R19代表取代或未取代的低级烷基等）等，R4代表取代或未取代的低级烷基等，R5代表取代或未取代的芳基等]等。
• Mitotic Kinesin Inhibitor
  申请人：KATO Kazuhiko

  公开号：US20110275827A1

  公开（公告）日：2011-11-10

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，该抑制剂包括由通式（I）所表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1表示氢原子等，R2表示氢原子，-C（═W）R6（其中W表示氧原子或硫原子，R6表示取代或未取代的低碳基等）等，R3表示-C（═Z）R19（其中Z表示氧原子或硫原子，R19表示取代或未取代的低碳基等）等，R4表示取代或未取代的低碳基等，R5表示取代或未取代的芳基等]等。